JPRN-UMIN000013669招募中2 期
A PhaseII study of XP(capecitabine plus cisplatin) combination therapy for HER2 negative advanced/recurrent gastric cancer - SGCSG G-04
SGCSG:Shimane Gstroenterological Vancer Study Group0 个研究点目标入组 36 人开始时间: 2014年4月8日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1)Forbidden case to use capecitabine and cisplatin. (2)R1 operation(histologically positive PM, OM, LM, VM). (3)Infection or inflammatory case. (4)Severe heart disease. (5)Severe complicated case such as ileus, intestitial pneumonia, uncontrolled DM, liver cirrhosis etc. (6)Difficulty to join the trial due to psychosis nervous system damage. (7)Complicated other active cancer. (8)patient who want to be pregnant and/or pregnant woman. (9)Intend to make pregnant. (10)Active hepatitis type HB positive(HBs antigen, HBc antibody and HBs antibody). (11)Otherwise determined by investigators or site principal investigators to be unsuitable for participation in study).
研究者
相似试验
已完成
2 期
A Phase II study of capecitabine plus cisplatin (plustrastuzumab) for previously untreated advanced gastric cancer.untreated advanced gastric cancerJPRN-UMIN000006458Ehime University45
已完成
2 期
A Phase II study of capecitabine plus cisplatin (plus trastuzumab) for previously untreated advanced gastric cancer.untreated advanced gastric cancerJPRN-UMIN000005998Department of Digestive surgery, Kawasaki Medical University53
已完成
不适用
A Phase II Study of Capecitabine, Oxaliplatin (XELOX) and Bevacizumab for patient with high-risk Upper Rectal Cancer as Neo-Adjuvant chemotherapy.pper rectal cancerJPRN-UMIN000015765Cancer Institute Hospital of Japanese Foundation for Cancer Research19
已完成
不适用
A phase II study of capecitabin plus oxaliplatin therapy (XELOX) for inoperable/advanced gastric cancer resistant/intolerable to fluoro-pyrimidine, CDDP, Taxane or CPT-11 (OGSG1403)unresectable/advanced gastric cancerJPRN-UMIN000016256Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG)12
已完成
2 期
PhaseII trial of capecitabine plus cisplatin in patients with recurrent HER-2 negative gastric cancer during or after the adjuvant chemotherapy using S-1 (T-CORE1102)HER2 negative gastric cancerJPRN-UMIN000006804Tohoku Clinical Oncoogy, Research and Education Society(T-CORE)21